Arvinas, Inc. reported $317M of revenue over the trailing twelve months, −15% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $317M (to Q2 2026). Net income: $9.3M, trailing twelve months to Q2 2026. Free cash flow: −$209M, trailing twelve months to Q2 2026. Operating margin: −308%, trailing twelve months to Q2 2026.

ARVNArvinas, Inc.

Healthcare

$7.52-19% 1Y

$7.52

$6.9852 weeks$13.83

ARVN as reported

Arvinas, Inc. reported $317M of revenue over the trailing twelve months, −15% on the year before. 9 reported series are charted on this page, each one as filed.

$317M

Revenue, trailing twelve months · to Q2 2026 · −15% against the twelve months before

Net income: $9.3M
Net income · −113% year on year · trailing twelve months to Q2 2026
Free cash flow: −$209M
Free cash flow · −48% year on year · trailing twelve months to Q2 2026
Operating margin: −308%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ARVN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$317M	−15%	Q2 2026
Net income	$9.3M	−113%	Q2 2026
EPS	$0.24	−124%	Q2 2026
Operating margin	−308%	n/a	Q2 2026
Net margin	−274%	n/a	Q2 2026
ROE	−21%	n/a	Q2 2026
ROA	−13%	n/a	Q2 2026
ROIC	109%	n/a	Q2 2026
Free cash flow	−$209M	−48%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.